The Future of Myopia Management: Occuity AX1 Axiometer™
Eyes on the Future: Occuity's Vienna Mission
Occuity makes FDA 510 (K) mark submission to sell the PM1 in the United States
Occuity to Showcase the PM1 and AX1 in Vienna to coincide with the 41st ESCRS Congress!
Shareholder Update - A view from the front
Occuity PM1 Clinical Trial Study Reported in Journal Ophthalmic & Physiological Optics (OPO)
Occuity Named Finalist for Hard Tech Investment of the Year at UK Business Angels Association
Occuity Recognised as a Top 13 European MedTech Startup to Watch by Sifted (Financial Times)
Monitoring Myopia Progression: Why Axial Length Measurements Are Taking the Lead
Occuity enters Boehringer Ingelheim start-ups acceleration program Synapse Acceleration®
CooperVision Sign Letter of Intent for AX1 Global Distribution
Tech Start-up of the Year...
Occuity becomes the largest MedTech raise ever on crowdfunding platform Seedrs, with £2.85m raise.
Crowdfunding Closes 10 pm Tonight
Longevitytech.fund make significant investment in Occuity
An Interview with Optometry Today
Gavin Sandison is a diabetic AND investor in Occuity...
We are now Overfunding!
Occuity launches £1.8m crowdfunding round to deliver ophthalmic and optical diabetes devices
#BehindTheRaise - an interview with Occuity Founder & CEO, Dr Dan Daly